330 related articles for article (PubMed ID: 16884450)
1. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics.
Tyson PJ; Laws KR; Flowers KA; Tyson A; Mortimer AM
Psychiatry Clin Neurosci; 2006 Aug; 60(4):473-9. PubMed ID: 16884450
[TBL] [Abstract][Full Text] [Related]
2. Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors?
Tyson PJ; Roberts KH; Mortimer AM
Int J Neurosci; 2004 Jun; 114(6):593-611. PubMed ID: 15204055
[TBL] [Abstract][Full Text] [Related]
3. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations.
J Clin Psychiatry; 1998; 59 Suppl 12():35-40. PubMed ID: 9766618
[TBL] [Abstract][Full Text] [Related]
5. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
Stahl SM; Shayegan DK
J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
[TBL] [Abstract][Full Text] [Related]
6. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
[TBL] [Abstract][Full Text] [Related]
7. Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics.
Watanabe A; Shibata I; Kato T
Psychiatry Clin Neurosci; 2004 Jun; 58(3):268-73. PubMed ID: 15149292
[TBL] [Abstract][Full Text] [Related]
8. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?
Meltzer HY; Sumiyoshi T
Behav Brain Res; 2008 Dec; 195(1):98-102. PubMed ID: 18707769
[TBL] [Abstract][Full Text] [Related]
9. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia.
Mori K; Nagao M; Yamashita H; Morinobu S; Yamawaki S
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):659-65. PubMed ID: 15276691
[TBL] [Abstract][Full Text] [Related]
10. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission.
Yen CF; Cheng CP; Huang CF; Yen JY; Ko CH; Chen CS
Bipolar Disord; 2008 Jul; 10(5):617-24. PubMed ID: 18657246
[TBL] [Abstract][Full Text] [Related]
11. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
Haleem DJ
J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
[TBL] [Abstract][Full Text] [Related]
12. Receptor mechanisms in the treatment of schizophrenia.
Reynolds GP
J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
[TBL] [Abstract][Full Text] [Related]
13. Conventional versus novel antipsychotics: changing concepts and clinical implications.
Remington G; Chong SA
J Psychiatry Neurosci; 1999 Nov; 24(5):431-41. PubMed ID: 10586534
[TBL] [Abstract][Full Text] [Related]
14. The influence of risperidone on cognitive functions in schizophrenia.
Barkić J; Filaković P; Radanović-Grgurić L; Koić O; Laufer D; Pozgain I; Koić E; Hotujac L
Coll Antropol; 2003; 27 Suppl 1():111-8. PubMed ID: 12955900
[TBL] [Abstract][Full Text] [Related]
15. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients.
Lee SM; Chou YH; Li MH; Wan FJ; Yen MH
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1101-7. PubMed ID: 17475386
[TBL] [Abstract][Full Text] [Related]
16. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
Millan MJ
J Pharmacol Exp Ther; 2000 Dec; 295(3):853-61. PubMed ID: 11082417
[TBL] [Abstract][Full Text] [Related]
17. Cognitive functioning related to quality of life in schizophrenia.
Matsui M; Sumiyoshi T; Arai H; Higuchi Y; Kurachi M
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):280-7. PubMed ID: 17884266
[TBL] [Abstract][Full Text] [Related]
18. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
Kuroki T; Nagao N; Nakahara T
Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
[TBL] [Abstract][Full Text] [Related]
19. On the trail of a cognitive enhancer for the treatment of schizophrenia.
Stip E; Chouinard S; Boulay LJ
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
[TBL] [Abstract][Full Text] [Related]
20. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
